Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NBIX
DateHeureSourceTitreSymboleSociété
23/01/202522h05PR Newswire (US)Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and DeviceNASDAQ:NBIXNeurocrine Biosciences Inc
21/01/202522h05PR Newswire (US)Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
17/01/202522h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
15/01/202522h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
08/01/202514h30PR Newswire (US)Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
06/01/202522h01PR Newswire (US)Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
20/12/202414h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
20/12/202414h00PR Newswire (US)Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
14/12/202400h55PR Newswire (US)Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
26/11/202422h01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in DecemberNASDAQ:NBIXNeurocrine Biosciences Inc
07/11/202414h30PR Newswire (US)Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
05/11/202422h01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in NovemberNASDAQ:NBIXNeurocrine Biosciences Inc
04/11/202414h30PR Newswire (US)Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
04/11/202414h25PR Newswire (US)Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive DyskinesiaNASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202412h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202412h00PR Newswire (US)Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
09/10/202422h01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
30/09/202414h30PR Newswire (US)Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic UseNASDAQ:NBIXNeurocrine Biosciences Inc
19/09/202422h01PR Newswire (US)Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual SummitNASDAQ:NBIXNeurocrine Biosciences Inc
12/09/202422h05PR Newswire (US)Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with SchizophreniaNASDAQ:NBIXNeurocrine Biosciences Inc
10/09/202422h01PR Newswire (US)Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
28/08/202422h05PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in SeptemberNASDAQ:NBIXNeurocrine Biosciences Inc
28/08/202413h00PR Newswire (US)Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with SchizophreniaNASDAQ:NBIXNeurocrine Biosciences Inc
07/08/202422h01PR Newswire (US)Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
01/08/202416h51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NBIXNeurocrine Biosciences Inc
01/08/202413h00PR Newswire (US)Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
18/07/202414h30PR Newswire (US)Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty SwallowingNASDAQ:NBIXNeurocrine Biosciences Inc
11/07/202422h01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
01/07/202413h30PR Newswire (US)Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAHNASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202414h01PR Newswire (US)Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024NASDAQ:NBIXNeurocrine Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NBIX